Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with Bevacizumab or other VEGF inhibitors or VEGFRs targeted agents. The gene discussed is VEGFA; the disease is peritoneum cancer.